Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03347617 · ClinicalTrials.gov registry record · Phase 2
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT03347617 is a Phase 2 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 52 participants.
The verdict
NCT03347617, a Phase 2 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This pilot phase II trial studies how well ferumoxytol magnetic resonance imaging (MRI) works in assessing response to pembrolizumab in patients with glioblastoma. Diagnostic procedures, such as ferumoxytol MRI, may help measure a patient's response to pembrolizumab treatment.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Ferumoxytol
- PROCEDURE Magnetic Resonance Imaging
- OTHER Laboratory Biomarker Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-12-20 |
| Est. Completion | 2025-06-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03347617
The ClinicalTrials.gov registry entry for NCT03347617 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03347617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03347617 about?
NCT03347617 is a clinical study titled "Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma". This pilot phase II trial studies how well ferumoxytol magnetic resonance imaging (MRI) works in assessing response to pembrolizumab in patients with glioblastoma. Diagnostic procedures, such as ferumoxytol MRI, may help measure a patient's response to pembrolizumab treatment.
What is the current status of trial NCT03347617?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2017-12-20. Estimated completion is 2025-06-23.
What interventions are being tested in trial NCT03347617?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Ferumoxytol (DRUG), Magnetic Resonance Imaging (PROCEDURE), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT03347617?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.